Prezcobix (darunavir/cobicistat) Tablets

Prezcobix is a prescription HIV medicine that combines two active ingredients in one tablet. Ships from Canada to US as part of a cross-border referral and dispensing model. This page explains what the medication is for, how it’s commonly used in a regimen, and what to know about safety and handling, including cash-pay access for people without insurance.

Because antiretroviral therapy is individualized, this overview stays high-level and label-aligned. It highlights the drug class, key precautions, and practical points to review with a prescriber or pharmacist before starting, stopping, or changing any HIV treatment.

What Prezcobix Is and How It Works

This medicine contains darunavir (an HIV-1 protease inhibitor) and cobicistat (a pharmacokinetic enhancer, meaning it boosts drug levels). Darunavir blocks an HIV enzyme called protease, which the virus needs to make mature infectious particles. Cobicistat slows the breakdown of darunavir by inhibiting CYP3A (a liver enzyme that metabolizes many medicines), helping maintain effective darunavir exposure when taken as directed with other antiretrovirals.

Dispensing occurs through licensed Canadian partner pharmacies. Some patients use this pathway for US shipping from Canada when local access is limited or cash-pay is preferred. The combination does not treat HIV by itself; it is prescribed as one component of a complete regimen selected by a healthcare professional.

Why it matters: Boosting can improve antiviral coverage but also increases interaction risk with other medications.

Who It’s For

Darunavir/cobicistat tablets are indicated for treatment of HIV-1 infection as part of combination antiretroviral therapy. In practice, a prescriber considers treatment history, prior resistance testing, and other medical conditions when selecting a regimen. For background on common care pathways and supportive resources, browse the HIV Condition Hub and related education on lab follow-up.

This therapy is not appropriate for everyone. It may be contraindicated with certain drugs that strongly interact through CYP3A pathways or that can cause serious, life-threatening effects when their levels rise. Severe liver disease may also limit use. People who are pregnant, have hepatitis co-infection, have kidney concerns, or take multiple chronic medications typically need extra review to reduce avoidable risks.

Diagnosis and monitoring often involve lab testing beyond viral load alone. For a plain-language overview of screening and confirmatory options, see Types Of HIV Tests.

Dosage and Usage

Label directions commonly describe one tablet taken once daily with food, alongside other antiretroviral medicines. The “with food” instruction matters because it helps with absorption of darunavir and supports consistent drug exposure. Tablets are generally swallowed whole; if swallowing is a concern, the prescriber can confirm what the product labeling allows and whether a different regimen is a better fit.

For Prezcobix dosing details, the official prescribing information and package insert outline who can use the fixed-dose tablet, how it is combined with other agents, and which co-administered medicines require adjustment or avoidance. If a dose is missed, labeling typically provides a time-based approach; the safest next step is to follow the written instructions provided with the prescription or confirm with a pharmacist, especially when multiple HIV medicines are involved.

Strengths and Forms

This product is supplied as an oral tablet that contains a fixed combination of darunavir 800 mg and cobicistat 150 mg (often written as 800/150 mg). Availability can vary by market and by pharmacy source, so the dispensed carton and bottle labeling should be checked for the exact presentation. Because it is a fixed-dose combination, the individual components cannot be independently adjusted within the same tablet.

The table below summarizes the common presentation described in labeling. If a clinician needs a different darunavir dose, another formulation or booster strategy may be selected instead of the fixed combination.

Storage and Travel Basics

Storage instructions in labeling generally recommend keeping the tablets at controlled room temperature and in the original container. Protect the medicine from excess heat and moisture, and keep the cap tightly closed. As with other prescription therapies, store it out of reach of children and pets, and avoid transferring tablets to unmarked containers that can increase mix-ups.

For travel, carrying medicines in hand luggage is often more practical than checking them, since temperature swings and lost baggage can interrupt therapy. Keeping a copy of the prescription label (or a medication list) can support smoother airport screening and help a clinician identify the exact product if urgent care is needed while away.

Quick tip: Save a photo of the bottle label in a secure folder for reference.

Side Effects and Safety

Like many antiretroviral medicines, this treatment can cause side effects that are uncomfortable but manageable for some patients. Commonly discussed effects include gastrointestinal upset (such as diarrhea or nausea), headache, tiredness, and skin rash. Lab changes may occur as well, including shifts in liver enzymes, cholesterol, or blood sugar, which is why routine monitoring is often part of ongoing HIV care.

More serious risks are uncommon but important to recognize early. Severe skin reactions, signs of liver problems (such as dark urine or yellowing skin), and symptoms that suggest an allergic-type reaction warrant urgent medical review. Because cobicistat can affect creatinine secretion, lab results may show a rise in serum creatinine without a true drop in kidney filtration; clinicians interpret this pattern in context and may track additional kidney markers when needed. Prescriptions are confirmed with the prescriber before filling.

Prezcobix may also be associated with immune reconstitution inflammatory syndrome (an immune rebound reaction) once HIV is controlled, especially in people starting therapy with advanced infection. A prescriber can explain what symptoms to watch for based on an individual’s history.

Drug Interactions and Cautions

Drug interaction screening is essential with boosted regimens because cobicistat is a strong CYP3A inhibitor and can affect other transporters. This means some medications can become too strong (increasing toxicity risk), while other drugs can reduce antiretroviral levels (raising the risk of treatment failure). High-risk categories can include certain heart rhythm drugs, sedatives, seizure medicines, antimycobacterials, migraine/ergot products, and herbal supplements such as St. John’s wort.

Prezcobix interactions also matter when combining therapy with other antivirals or chronic treatments. For example, some cholesterol medicines, anticoagulants, inhaled or nasal steroids, and immunosuppressants may require careful selection or dose modification. A complete, up-to-date medication list should include over-the-counter products and supplements, not only prescriptions. To browse related therapies by class, see the Antivirals Category hub.

Compare With Alternatives

HIV treatment is typically built from multiple drug classes, and the best regimen can differ by treatment history, resistance patterns, kidney or liver health, and interaction concerns. Prezcobix is one boosted protease inhibitor option; clinicians sometimes compare it with other protease inhibitor–based regimens or with integrase inhibitor–based combinations, depending on goals and tolerability. These comparisons should rely on current guidelines and individualized clinical judgment rather than one-size-fits-all rules.

Within the same general class, another protease inhibitor product sometimes referenced in HIV care is Aptivus 250 mg, though it is not interchangeable and has its own labeling and interaction profile. Some patients also manage related conditions alongside HIV therapy; examples in a broader care plan may include Tesamorelin Overview for certain HIV-associated body fat changes, or Vemlidy Overview in hepatitis B management when clinically appropriate. For a wider discussion of how regimens evolve over time, read HIV Treatment Landscape.

Pricing and Access

Costs for branded antiretrovirals can be significant, and the total expense often depends on the full regimen, dispensing channel, and whether patient assistance is available. BorderFreeHealth supports cross-border access by coordinating with Canadian dispensing partners and facilitating documentation needed for a valid prescription. Access is available on a cash-pay basis when coverage is limited.

For people who are managing a budget, it can help to ask about refill timing, whether the full regimen can be synchronized, and which pharmacy documents are required for continuity. Those exploring Prezcobix cost options may also review Current Promotions when applicable, while keeping the prescriber’s regimen plan unchanged. Any substitution within HIV therapy should be clinician-led due to resistance and interaction considerations.

Authoritative Sources

For the most accurate details, refer to the official prescribing information and medication guide provided with the dispensed product. These sources include contraindications, interaction tables, and special-population considerations that cannot be fully summarized on a single page.

For neutral, official labeling references, the following resources can help:

• DailyMed listing for U.S. labeling text
• NIH ClinicalInfo drug information search results

To submit a prescription referral request, choose prompt, express shipping at checkout if offered.

This content is for informational purposes only and is not a substitute for professional medical advice.